BON NAT LIFE Appeals After Dual Nasdaq Delisting Notices
By ATTN Desk · Editorial oversight: Sean Han
Introduction
BON NAT LIFE LTD (Nasdaq: BON) is a Cayman Islands–incorporated biotechnology firm founded in 2006 and based in Xi’an High-tech Zone, Shaanxi Province, China. Operating under the trade name Xi’an App-Chem Bio (Tech) Co., Ltd., the company specializes in extracting and processing plant-based ingredients for use in food, dietary supplements, cosmetics, and personal care products.
Corporate Structure and Operations
BON NAT LIFE LTD employs between 11 and 50 staff members across research, production, and quality assurance functions. Its facilities hold ISO9001, ISO22000, and US FDA inspection certifications. The company’s innovation efforts are supported by over 30 granted patents and more than 70 registered trademarks. Core activities include:
- Extraction of all-natural chemical compounds from plants
- Development of ingredient solutions for functional foods and personal care
- Customer-centric research and development and technical support
Biotechnology by Sangharsh Lohakare
Developments and News
- On May 2, 2025, the company announced receipt of two Nasdaq delisting notifications. The first notification related to non-compliance with the $1.00 minimum bid price rule over 30 consecutive trading days. The second notification cited public interest concerns linked to a March 2025 best-efforts offering.
- BON NAT LIFE LTD filed an appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to stay the delisting process. The outcome and timeline of that appeal remain pending.
- As of September 9, 2025, BON shares closed at $3.49, with a trading volume of 10,651,280 shares.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-09-09) | $3.49 |
| Day’s Change | +126.62% |
| 52-Week Range | $1.14 – $73.75 |
| Market Capitalization | $5.56 M |
| Enterprise Value | $12.78 M |
| Trailing P/E Ratio (TTM) | 0.35 |
| EPS (TTM) | 4.25 |
| Revenue (TTM) | $23.84 M |
| Net Income (TTM) | $0.42 M |
| Price/Sales (TTM) | 0.01 |
| Price/Book (MRQ) | 0.13 |
| Profit Margin | 1.67% |
| Return on Assets (TTM) | 2.16% |
| Return on Equity (TTM) | 0.91% |
| Total Cash (MRQ) | $80.47 K |
| Total Debt/Equity (MRQ) | 17.01% |
| Levered Free Cash Flow (TTM) | -$8.58 M |
Strategically, the company's low valuation multiples (P/S of 0.01, P/B of 0.13) reflect its scale and cash constraints. It generated a profit on a trailing basis, but negative free cash flow highlights funding requirements for research and development as well as regulatory compliance. The pending Nasdaq appeal is critical for maintaining a U.S. listing and access to public capital markets.
Market Position and Industry Context
Operating in the natural health and personal care sectors, BON NAT LIFE LTD competes with regional and international ingredient suppliers. Its focus on all-natural, plant-derived compounds aligns with consumer and regulatory trends favoring sustainable and traceable raw materials. The company’s certifications, patent portfolio, and customer-focused services aim to position it within a market characterized by low barriers to entry but stringent quality requirements.
tl;dr
On May 2, 2025, BON NAT LIFE LTD received Nasdaq delisting notices for failing to meet the $1.00 minimum bid price and public interest standards. The company has appealed and secured a hearing to stay the delisting process, while its share price stood at $3.49 on September 9, 2025. The outcome of the appeal will influence BON’s continued presence on Nasdaq and its capacity to raise capital for its plant-based ingredient business.